News | March 18, 2015

Mitral Valve, Surgical Ablation Combination Frees Patients of Atrial Fibrillation

Study results show no significant increase in mortality, adverse cardiac events or hospitalizations

CTSN, atrial fibrillation, surgical ablation, mitral valve surgery

March 18, 2015 — New study results from The Cardiothoracic Surgical Trials Network (CTSN) show the addition of surgical ablation during mitral valve surgery reduces the occurrence of atrial fibrillation in patients.

The findings — presented March 16 at the American College of Cardiology 64th Annual Scientific Sessions in San Diego and published simultaneously in the New England Journal of Medicine (NEJM) — show a significant amount of patients were free from atrial fibrillation after one year when they received an additional surgical ablation procedure instead of mitral valve surgery alone. Also, the study showed no significant increase in mortality, adverse cardiac events or hospitalizations by adding a surgical ablation procedure to disrupt chaotic electrical signals from atrial fibrillation, which can cause abnormal heart rhythms.

Among those patients receiving ablation, 63 percent were free from atrial fibrillation at six and 12 months after surgery. Only 29 percent who received mitral valve surgery alone were free from atrial fibrillation.

“I think what this shows is that, in the mitral valve surgery patient who has persistent atrial fibrillation, you will achieve better rhythm control by performing ablation, without any increase in mortality or other adverse cardiac events,” said Marc Gillinov, M.D., the Judith Dion Pyle Chair in Heart Valve Research at Cleveland Clinic and the study’s lead author who presented the study.

Approximately 30-50 percent of patients who undergo mitral valve surgery to repair their weak, leaky or hardened valve experience atrial fibrillation, which is a dangerous heart rhythm disorder linked to increased risk of death and stroke. Currently, evidence regarding the safety and effectiveness of surgical ablation has been limited, leading to considerable variation in its use at the time of mitral valve surgery.

“The good news is that a significant proportion of mitral valve surgery patients with atrial fibrillation are already receiving the additional surgical ablation therapy,” said Michael Argenziano, M.D., section chief of adult cardiac surgery at NewYork- Presbyterian/Columbia University Medical Center, associate professor of surgery at Columbia University Medical Center and the study’s senior author. “Our study’s results support this practice and will hopefully lead to even greater adoption of this procedure, allowing more surgical patients to avoid the risks associated with atrial fibrillation.”

To assess its effectiveness as an adjunct procedure to mitral valve surgery, 20 institutions in the United States and Canada enrolled 260 patients with persistent or long-standing persistent atrial fibrillation. These patients received mitral valve surgery alone or mitral valve surgery plus surgical ablation. Patients who were randomly assigned to surgical ablation underwent either pulmonary-vein isolation or the bi-atrial maze procedure. All patients underwent standard left atrial appendage closure during mitral valve surgery to further reduce their risk of stroke.

“The only downside associated with surgical ablation was a 2.5 times greater likelihood of needing a pacemaker implant in the year following their surgery,” said Annetine C. Gelijns, Ph.D., professor and chair of the Department of Population Health Science and Policy at Icahn School of Medicine at Mount Sinai; Gelijns is the corresponding author for the NEJM study and principal investigator for the Data and Clinical Coordinating Center based at Mount Sinai for the NIH-sponsored Cardiothoracic Surgical Trials Network (CTSN). “As such, patients will have to weigh the benefits of a higher probability of being free of atrial fibrillation — with a reduction in its associated complications — versus the higher likelihood of receiving pacemakers.”

This CTSN trial was conducted at eight core clinical centers in the United States and Canada.

For more information: www.ctsurgerynet.org

Related Content

DISRUPT BTK Study Shows Positive Results With Lithoplasty in Calcified Lesions Below the Knee
News | Peripheral Artery Disease (PAD)| September 20, 2017
Shockwave Medical reported positive results from the DISRUPT BTK Study, which were presented at the annual...
Gecko Biomedical Receives CE Mark Approval for Setalum Sealant
News | Cardiovascular Surgery| September 19, 2017
Gecko Biomedical announced it has received CE Mark approval for its Setalum Sealant, allowing the company to market its...
Corindus Announces First Patient Enrolled in PRECISION GRX Registry
News | Robotic Systems| September 18, 2017
September 18, 2017 — Corindus Vascular Robotics Inc.
Two-Year ILLUMENATE Trial Data Demonstrate Efficacy of Stellarex Drug-Coated Balloon
News | Drug-Eluting Balloons| September 18, 2017
Philips announced the two-year results from the ILLUMENATE European randomized clinical trial (EU RCT) demonstrating...
Sentinel Cerebral Protection System Significantly Reduces Stroke and Mortality in TAVR
News | Embolic Protection Devices| September 18, 2017
September 18, 2017 – Claret Medical announced publication of a new study in the...
Fysicon Receives FDA Approval for QMAPP Hemodynamic Monitoring System
Technology | Hemodynamic Monitoring Systems| September 18, 2017
Fysicon announced that it has been granted 510(k) clearance by the U.S. Food and Drug Administration (FDA) for its...
Marijuana Associated With Three-Fold Risk of Death From Hypertension
News | Hypertension| September 14, 2017
Marijuana use is associated with a three-fold risk of death from hypertension, according to research published recently...
Peter Schneider, M.D. presents late breaking clinical trial results at VIVA 17 in Las Vegas. Panelists (l to r) Krishna Rocha-Singh, M.D., Sean Lyden, M.D., John Kaufman, M.D., Donna Buckley, M.D.

Peter Schneider, M.D. presents late breaking clinical trial results at VIVA 17 in Las Vegas. Panelists (l to r) Krishna Rocha-Singh, M.D., Sean Lyden, M.D., John Kaufman, M.D., Donna Buckley, M.D.

Feature | Cath Lab| September 14, 2017
September 14, 2017 — Here are quick summaries for all the key late-breaking vascular and endovascular clinical trials
Medtronic Announces Japanese Regulatory Approval for In.Pact Admiral Drug-Coated Balloon
News | Drug-Eluting Balloons| September 13, 2017
Medtronic plc announced that the In.Pact Admiral Drug-Coated Balloon (DCB) received approval from the Japanese Ministry...
Overlay Init